Hundreds of people with an aggressive type of blood cancer, known as diffuse large B-cell lymphoma (DLBCL) are set to benefit from a potentially curative new treatment option on the NHS, with approval of the drug glofitamab. Glofitamab (also called Columvi®) is to be made available for patients with previously treated DLBCL which is a […]
Read More on the NHS website.